Lanvis

Tioguanine, the active ingredient in Lanvis, is a thiopurine antimetabolite presented as an oral tablet for systemic use. It is employed in the treatment of certain leukemias and inflammatory bowel disease.

GNH USA supplies Lanvis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lanvis is a thiopurine antimetabolite that acts on rapidly dividing cells in hematologic malignancies and immune‑mediated disorders.

Acute myeloid leukemia: used as part of induction or consolidation therapy to reduce leukemic cell proliferation. Chronic myelogenous leukemia: incorporated into treatment regimens to achieve cytoreduction. Inflammatory bowel disease: employed to maintain remission by suppressing immune activity.

Adverse reactions may occur with Tioguanine therapy and should be monitored.

Common Side Effects: - Nausea or vomiting - Diarrhea or abdominal discomfort - Fatigue or lethargy - Mild leukopenia or neutropenia - Rash or mild skin irritation - Elevated liver enzymes

Serious or Rare Side Effects: - Severe bone‑marrow suppression (pancytopenia) - Hepatotoxicity or hepatic failure - Life‑threatening infections - Pancreatitis - Secondary malignancies - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome)

Tioguanine requires careful monitoring and patient education before and during therapy. - Blood count monitoring: regular CBC to detect leukopenia or anemia. - Liver function: periodic LFTs to identify hepatotoxicity. - Infection risk: avoid use in patients with active severe infections. - Dose adjustment: consider renal or hepatic impairment when dosing. - Pregnancy and lactation: safety not established; use only if benefits outweigh risks. - Storage: Store below 25°C: keep in the original container, protect from moisture and light.

Tioguanine may interact with several medicines, altering its efficacy or toxicity.

Major Interactions (Avoid): - Allopurinol or other xanthine oxidase inhibitors: can markedly increase thioguanine toxicity. - Azathioprine: additive myelosuppression risk. - Warfarin: may enhance anticoagulant effect.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase risk of gastrointestinal irritation. - Sulfonamide antibiotics: potential for additive bone‑marrow suppression. - Antiviral agents (e.g., acyclovir): may affect hepatic metabolism. - Methotrexate: combined immunosuppression may require closer monitoring.